Infliximab biosimilar linked to increased risk of uveitis flares
- Posted on: Dec 3 2020
- Leave a response
This retrospective study measured recurrence of inflammation after switching from original infliximab (Remicade) to a biosimilar for noninfectious uveitis.
Source: AAO
Posted in: Uncategorized
